Pharmathene, Inc. (Pharmathene) is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.
Industry, Sector and Symbol:
- Sector: Finance
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NYSE:PIP
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $0.77
- 200 Day Moving Avg: $2.08
- 52 Week Range: $0.47 - $3.50
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.29
- P/E Growth: 0.00
- Average Volume: 4.43 million shs.
Frequently Asked Questions for PharmAthene (NYSE:PIP)
What is PharmAthene's stock symbol?
PharmAthene trades on the New York Stock Exchange (NYSE) under the ticker symbol "PIP."
How often does PharmAthene pay dividends? What is the dividend yield for PharmAthene?
PharmAthene declared a special dividend on Monday, November 21st. Investors of record on Sunday, January 24th will be given a dividend of $2.91 per share on Friday, February 3rd. The ex-dividend date of this dividend is Monday, February 6th. View PharmAthene's Dividend History.
How were PharmAthene's earnings last quarter?
PharmAthene, Inc. (NYSE:PIP) posted its quarterly earnings results on Monday, March, 9th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $1.83 million for the quarter. View PharmAthene's Earnings History.
Who are some of PharmAthene's key competitors?
Some companies that are related to PharmAthene include HDFC Bank Limited (HDB), Berkshire Hathaway (BRK-A), Berkshire Hathaway (BRK.B), Berkshire Hathaway (BRK.A), J P Morgan Chase & Co (JPM), Wells Fargo & Company (WFC), Bank of America Corporation (BAC), HSBC Holdings PLC (HSBC), Citigroup (C), Royal Bank Of Canada (RY), Banco Santander, S.A. (SAN), Toronto Dominion Bank (The) (TD), Allianz SE (AZSEY), Goldman Sachs Group, Inc. (The) (GS), U.S. Bancorp (USB), Morgan Stanley (MS), Westpac Banking Corporation (WBK) and Mitsubishi UFJ Financial Group (MTU).
Who owns PharmAthene stock?
PharmAthene's stock is owned by many different of retail and institutional investors. Top institutional investors include
NOVARTIS BIOVENTURES LTD
TRUFFLE CAPITAL S.A.S.
(10.10%). Company insiders that own PharmAthene stock include Eric I Richman and Prescott Group Capital Managem. View Institutional Ownership Trends for PharmAthene.
How do I buy PharmAthene stock?
Shares of PharmAthene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PharmAthene's stock price today?
MarketBeat Community Rating for PharmAthene (NYSE PIP)MarketBeat's community ratings are surveys of what our community members think about PharmAthene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of PharmAthene stock can currently be purchased for approximately $0.65.
Consensus Ratings for PharmAthene (NYSE:PIP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for PharmAthene (NYSE:PIP)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for PharmAthene (NYSE:PIP)Earnings History by Quarter for PharmAthene (NYSE PIP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2014||($0.03)||($0.07)||$3.50 million||$0.96 million||View||N/A|
Earnings Estimates for PharmAthene (NYSE:PIP)
Current Year EPS Consensus Estimate: $-0.10 EPS
Next Year EPS Consensus Estimate: $-0.07 EPS
Current Dividend Information for PharmAthene (NYSE:PIP)
|Most Recent Dividend:||2/3/2017|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||0.00% (Based on This Year's Estimates)|
0.00% (Based on Next Year's Estimates)
Dividend History by Quarter for PharmAthene (NYSE PIP)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for PharmAthene (NYSE:PIP)Insider Trades by Quarter for PharmAthene (NYSE:PIP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/9/2016||Prescott Group Capital Managem||Major Shareholder||Sell||1,354,632||$3.26||$4,416,100.32|| |
|4/13/2016||Eric I Richman||Director||Sell||329,354||$2.20||$724,578.80|| |
|4/8/2016||Eric I Richman||Director||Sell||11,767||$2.20||$25,887.40|| |
|3/19/2015||Peter Steven St||Director||Buy||25,000||$1.65||$41,250.00|| |
|1/7/2015||Linda L Chang||CFO||Sell||29,600||$2.10||$62,160.00|| |
|9/22/2014||Prescott Group Capital Managem||Major Shareholder||Buy||15,000||$1.55||$23,250.00|| |
Headline Trends for PharmAthene (NYSE:PIP)
Latest Headlines for PharmAthene (NYSE:PIP)
|PharmAthene, Inc. (PIP) Sees Large Decrease in Short Interest|
www.americanbankingnews.com - May 10 at 7:00 AM
|Today's Research Reports on Biotech Stocks to Watch: AVEO Pharmaceuticals and PharmAthene|
finance.yahoo.com - May 5 at 8:41 AM
|PharmAthene (PIP) Earning Positive Media Coverage, Study Shows|
www.americanbankingnews.com - May 4 at 2:56 PM
|PharmAthene reports 1Q loss|
finance.yahoo.com - May 4 at 8:15 AM
|PharmAthene Reports First Quarter 2017 Financial and Operational Results - PR Newswire (press release)|
www.prnewswire.com - May 3 at 7:47 PM
|PharmAthene Reports First Quarter 2017 Financial and Operational Results|
finance.yahoo.com - May 3 at 7:47 PM
|PharmAthene (PIP) Earns Daily Media Sentiment Score of 0.21|
www.americanbankingnews.com - April 30 at 5:45 PM
|PharmAthene (PIP) Given News Impact Score of 0.01|
www.americanbankingnews.com - April 27 at 6:50 PM
|PharmAthene (PIP), Altimmune Combination Approved to Trade on Nasdaq Global Under Ticker ALT (ALT)|
www.streetinsider.com - April 26 at 11:06 PM
|PharmAthene (PIP), Altimmune Combination Approved to Trade on Nasdaq Global Under Ticker ALT (ALT) - StreetInsider.com|
www.streetinsider.com - April 26 at 6:02 PM
|PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market|
finance.yahoo.com - April 26 at 6:02 PM
|ETFs with exposure to PharmAthene, Inc. : April 19, 2017|
finance.yahoo.com - April 19 at 7:13 PM
|Somewhat Critical Media Coverage Somewhat Likely to Impact PharmAthene (PIP) Share Price|
www.americanbankingnews.com - April 17 at 5:01 PM
|PharmAthene (PIP) Given Daily News Impact Score of -0.10|
www.americanbankingnews.com - April 14 at 1:08 PM
|PharmAthene, Inc. (PIP) Sees Large Increase in Short Interest|
www.americanbankingnews.com - April 11 at 7:11 PM
|ETFs with exposure to PharmAthene, Inc. : April 7, 2017|
finance.yahoo.com - April 7 at 7:37 PM
|PHARMATHENE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
biz.yahoo.com - March 29 at 7:58 PM
|Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™|
finance.yahoo.com - March 28 at 9:44 AM
|PharmAthene, Inc. (PIP) Short Interest Update|
www.americanbankingnews.com - March 25 at 7:14 AM
|PHARMATHENE, INC Financials|
finance.yahoo.com - March 18 at 6:36 PM
|PharmAthene Reports Year-End 2016 Financial and Operational Results|
finance.yahoo.com - March 14 at 6:44 PM
|PHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statement|
biz.yahoo.com - March 14 at 6:44 PM
|PharmAthene Announces Record Date and Meeting Date for Special Meeting of Stockholders Regarding Proposed Merger Transaction with Altimmune|
finance.yahoo.com - March 13 at 9:46 AM
|PharmAthene, Inc. (PIP) Short Interest Down 56.8% in February|
www.americanbankingnews.com - March 9 at 6:30 PM
|Pepsico CFO: We have terrific momentum|
finance.yahoo.com - February 16 at 6:51 PM
|Pepsico CFO: Great business in Mexico|
finance.yahoo.com - February 16 at 6:51 PM
|Biotech Premarket Movers: PharmAthene, Earth Science Tech, Pulmatrix|
www.thestreet.com - February 7 at 9:03 PM
|Altimmune to Present at the BIO CEO & Investor Conference|
finance.yahoo.com - February 6 at 9:06 AM
|Form 425 PHARMATHENE, INC Filed by: PHARMATHENE, INC|
www.streetinsider.com - February 1 at 9:41 PM
|[$$] Gormley's Take: As IPO Market Tightens, Biotechs Find Another Route to Public Listing|
www.wsj.com - February 1 at 9:41 PM
|PharmAthene and Altimmune to Merge in All-Stock Deal|
www.investopedia.com - January 23 at 7:33 PM
|Two of region's anthrax-fighting companies announce merger|
us.rd.yahoo.com - January 20 at 8:05 PM
|PharmAthene (PIP), Altimmune to Merge in All-Stock Transaction - StreetInsider.com|
www.streetinsider.com - January 20 at 1:18 AM
|PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases|
finance.yahoo.com - January 20 at 1:18 AM
|6:32 am PharmAthene and privately-held Altimmune announce merger in an all-stock transaction|
finance.yahoo.com - January 20 at 1:17 AM
|PHARMATHENE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off|
biz.yahoo.com - January 20 at 1:17 AM
|Mid-Afternoon Market Update: Dow Slides Over 100 Points; CSX Shares Spike Higher|
feeds.benzinga.com - January 19 at 4:05 PM
PharmAthene (PIP) Chart for Sunday, July, 23, 2017